Integra Lifesciences Holdings Corp (IART) : Mitsubishi Ufj Securities Holdings Ltd. added new position in Integra Lifesciences Holdings Corp during the most recent quarter end. The investment management firm now holds 17,801 shares of Integra Lifesciences Holdings Corp which is valued at $1.3 Million , the company said in a statement filed on May 13, 2016 with the SEC.Integra Lifesciences Holdings Corp makes up approximately 3.31% of Mitsubishi Ufj Securities Holdings Ltd.’s portfolio.
Other Hedge Funds, Including , Netols Asset Management reduced its stake in IART by selling 16,223 shares or 11.87% in the most recent quarter. The Hedge Fund company now holds 120,399 shares of IART which is valued at $8.6 Million. Integra Lifesciences Holdings Corp makes up approx 1.94% of Netols Asset Management’s portfolio.Boston Partners boosted its stake in IART in the latest quarter, The investment management firm added 4,643 additional shares and now holds a total of 463,159 shares of Integra Lifesciences Holdings Corp which is valued at $32.9 Million. Integra Lifesciences Holdings Corp makes up approx 0.05% of Boston Partners’s portfolio.Russell Frank Co reduced its stake in IART by selling 67,645 shares or 20.45% in the most recent quarter. The Hedge Fund company now holds 263,159 shares of IART which is valued at $18.6 Million. Integra Lifesciences Holdings Corp makes up approx 0.03% of Russell Frank Co’s portfolio.
Integra Lifesciences Holdings Corp opened for trading at $72.68 and hit $73.52 on the upside on Wednesday, eventually ending the session at $73.24, with a gain of 0.84% or 0.61 points. The heightened volatility saw the trading volume jump to 2,32,737 shares. Company has a market cap of $2,726 M.
On the company’s financial health, Integra Lifesciences Holdings Corp reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.73. The company had revenue of $236.80 million for the quarter, compared to analysts expectations of $230.83 million. The company’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.76 EPS.
Many Wall Street Analysts have commented on Integra Lifesciences Holdings Corp. Company shares were Reiterated by Barclays on Apr 28, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 74 from a previous price target of $70 .
Integra LifeSciences Holdings Corporation is a medical technology company. The Company offers solutions such as orthopedic extremity surgery neurosurgery spine surgery and reconstructive and general surgery. The Company’s operating segments are: Specialty Surgical Solutions and Orthopedics and Tissue Technologies. The Company’s Specialty Surgical Solutions segment includes the Neurosurgery business and the Instruments business. The Company’s Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair bone and joint fixation implants in the upper and lower extremities bone grafts and nerve and tendon repair. The Company sources its handheld surgical instruments and specialty metal and pyrocarbon implants through third-party vendors. The Company manufactures its products in plants which are located in the United States Puerto Rico France Germany Ireland and Mexico.